Cargando…
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
Autores principales: | Pirosa, Maria Cristina, Sassone, Marianna, Kiesewetter, Barbara, Guillermo, Armando Lopez, Devizzi, Liliana, Domènech, Eva Domingo, Tucci, Alessandra, Mannina, Donato, Merli, Michele, Salar, Antonio, Visco, Carlo, Esposito, Fabiana, Bonomini, Luisella, Zucca, Emanuele, Ferreri, Andrés J. M., Raderer, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230432/ https://www.ncbi.nlm.nih.gov/pubmed/36546422 http://dx.doi.org/10.3324/haematol.2022.281963 |
Ejemplares similares
-
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial
por: Joerger, M, et al.
Publicado: (2010) -
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal
por: Raderer, Markus, et al.
Publicado: (2023) -
Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum
por: Kiesewetter, Barbara, et al.
Publicado: (2018) -
Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients
por: Bilgilier, Ceren, et al.
Publicado: (2016) -
Recent results from CLEO and the CESR-CLEO Charm factory
por: Shipsey, Ian
Publicado: (2001)